More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$10.08B
EPS
6.12
P/E ratio
25.3
Price to sales
3.07
Dividend yield
--
Beta
1.057673
Previous close
$145.29
Today's open
$144.69
Day's range
$142.24 - $148.49
52 week range
$126.40 - $354.88
show more
CEO
Ashley McEvoy
Employees
5400
Headquarters
Acton, MA
Exchange
Nasdaq Global Select
Shares outstanding
69371043
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Benzinga • 5 hours ago

Insulet Corporation (PODD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Insulet Corporation (PODD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 4 hours ago

Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Nov 12, 2026

Insulet (PODD) Just Overtook the 20-Day Moving Average
After reaching an important support level, Insulet (PODD) could be a good stock pick from a technical perspective. PODD surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Zacks Investment Research • Nov 12, 2026

Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter
Insulet is undervalued, trading at a sub-median multiple despite 20% revenue growth and expanding margins. PODD's pharmacy-based, fully disposable model and dominant new patient onboarding differentiate it from emerging tubeless competitors. Record gross margins (74.2%) and upgraded guidance—2026 revenue growth of 21%-22% and adjusted EPS growth above 30%—underscore strong operating leverage.
Seeking Alpha • Nov 11, 2026

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Zacks Investment Research • Nov 10, 2026

For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being
ACTON, Mass.--(BUSINESS WIRE)--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and mental demands of living with diabetes and encourage people living with diabetes to prioritize their own well-being. “Living with d.
Business Wire • Nov 9, 2026

What Insulet (PODD) Said on Its Q3 Earnings Call
Insulet NASDAQ: PODD reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company's plans and U.S. performance landed within its guidance range.
MarketBeat • Nov 4, 2026

Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript
Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Insulet Reports Third Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Revenue of $842.0 million, up 19.2%, or 19.6% in constant currency, slightly above the high end of the Company's guidance range of 17.5% - 19.5% at constant currency rates Total Omnipod revenue o.
Business Wire • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Insulet Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.